Anti-programmed cell death-1 ligand-1 (PD-L1) antibody (atezolizumab) and anti-vascular endothelial growth factor (VEGF) antibody (bevacizumab) are considered standard-of-care, first-line, systemic agents for advanced HCC, yet yield a 27.3% objective response rate and 13.9-month survival rate in patients with a baseline AFP ≥ 400 ng/mL [3]. The gene discussed is VEGFA; the disease is hepatocellular carcinoma.